Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ovid Therapeutics
Biotech
Takeda axes epilepsy asset after FDA weighs in on data package
The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its clinical data package.
Nick Paul Taylor
Jan 30, 2025 7:19am
Ovid pauses ph. 2 plans for ROCK2 inhibitor to mull rival's data
Nov 13, 2024 8:15am
Ovid halts preclinical work, IV program after soticlestat fail
Aug 13, 2024 9:15am
Takeda flunks pivotal epilepsy tests but mulls path to market
Jun 17, 2024 8:50am
Ovid sells some royalty rights to Takeda-partnered seizure drug
Oct 18, 2023 8:00am
Ovid snaps up Rock2 inhibitor from Sam Waksal-led Graviton
May 1, 2023 11:06am